Compounded Peptides ·
Compounded semaglutide was the first GLP-1 compounded drug to achieve mass-market scale, beginning in 2022 when Novo Nordisk's Ozempic and Wegovy appeared on the shortage list. Telehealth platforms offering $200/month compounded semaglutide programs demonstrated that consumer demand for affordable GLP-1 therapy far exceeded the branded supply. That commercial template — online consultation, compounded preparation, direct-to-patient shipping — became the blueprint for compounded tirzepatide and eventually for the more legally tenuous compounded retatrutide. Understanding how the semaglutide market developed is essential context for the 2026 regulatory and litigation environment.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.